• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Officer Rodriguez Javier converted options into 9,000 shares, increasing direct ownership by 131% to 15,863 units (SEC Form 4)

    5/7/26 7:00:12 PM ET
    $BTAI
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $BTAI alert in real time by email
    SEC FORM 4SEC Form 4
    FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number:3235-0287
    Estimated average burden
    hours per response:0.5
      
    Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
      
    Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
    1. Name and Address of Reporting Person*
    Rodriguez Javier

    (Last)(First)(Middle)
    C/O BIOXCEL THERAPEUTICS, INC.
    555 LONG WHARF DRIVE, 12TH FLOOR

    (Street)
    NEW HAVEN CONNECTICUT 06511

    (City)(State)(Zip)

    UNITED STATES

    (Country)
    2. Issuer Name and Ticker or Trading Symbol
    BioXcel Therapeutics, Inc. [ BTAI ]
    5. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    Director10% Owner
    XOfficer (give title below)Other (specify below)
    See Remarks
    2a. Foreign Trading Symbol
    3. Date of Earliest Transaction (Month/Day/Year)
    05/01/2026
    6. Individual or Joint/Group Filing (Check Applicable Line)
    XForm filed by One Reporting Person
    Form filed by More than One Reporting Person
    4. If Amendment, Date of Original Filed (Month/Day/Year)

    Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
    1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
    CodeVAmount(A) or (D)Price
    Common Stock05/01/2026M9,000A(1)15,863D
    Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
    CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
    Restricted Stock Units(1)05/01/2026M9,000 (2) (2)Common Stock9,000$00D
    Explanation of Responses:
    1. Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock.
    2. On August 1, 2025 (the "Grant Date"), the Reporting Person was granted 9,000 RSUs, vesting as to 100% on or within thirty (30) days of 9 months from the Grant Date, subject to the Reporting Person's continued employment with the Issuer or a subsidiary of the Issuer on such date.
    Remarks:
    Chief Legal Officer, Senior Vice President and Corporate Secretary
    /s/ Richard Steinhart, Attorney-in-Fact for Javier Rodriguez05/07/2026
    ** Signature of Reporting PersonDate
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    * Form 4: SEC 1474 (03-26)
    Get the next $BTAI alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $BTAI

    DatePrice TargetRatingAnalyst
    3/17/2026$17.00Buy
    Rodman & Renshaw
    2/21/2024$9.00 → $4.00Buy → Neutral
    UBS
    8/15/2023$40.00 → $4.00Buy → Neutral
    Mizuho
    7/17/2023Buy → Neutral
    Guggenheim
    3/10/2023$20.00 → $22.00Buy → Hold
    Jefferies
    12/1/2022$16.00Sell → Neutral
    Goldman
    7/7/2022$19.00Buy
    Mizuho
    4/6/2022$80.00Buy
    BofA Securities
    More analyst ratings

    $BTAI
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    BioXcel Therapeutics Presents New Data from SERENITY At-Home Phase 3 Trial for Agitation Associated with Bipolar Disorders or Schizophrenia at 2026 ASCP Annual Meeting

    NEW HAVEN, Conn., May 28, 2026 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (NASDAQ:BTAI), a biopharmaceutical company built on artificial intelligence ("AI") to develop transformative medicines in neuroscience, today announced the presentation of new positive data from the Phase 3 SERENITY At-Home trial evaluating BXCL501 (sublingual dexmedetomidine) for the acute treatment of agitation associated with bipolar disorders or schizophrenia in the at-home setting at the 2026 American Society of Clinical Psychopharmacology (ASCP) Annual Meeting, taking place May 26 – 29 in Miami, FL. Positive primary results from the randomized, double-blind, placebo-controlled Phase 3 SERENITY At-Home safe

    5/28/26 7:00:00 AM ET
    $BTAI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    BioXcel Therapeutics Provides Business Update and Reports First Quarter 2026 Financial Results

    FDA accepted sNDA for IGALMI® use in at-home (outpatient) setting; set Nov. 14, 2026, as PDUFA date  Advancing BXCL501 as a potential acute treatment for agitation associated with Alzheimer's dementia Evaluating strategic options with an advisor to maximize shareholder value and advance the commercial and development plans for IGALMI NEW HAVEN, Conn., May 15, 2026 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (NASDAQ:BTAI), a biopharmaceutical company built on artificial intelligence ("AI") to develop transformative medicines in neuroscience, today provided a business update and reported financial results for the first quarter of 2026. In the quarter ended on March 31, the

    5/15/26 7:00:00 AM ET
    $BTAI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    BioXcel Therapeutics Announces Virtual Event to Discuss Commercial Launch Plan Based on Market Opportunity Assessment for IGALMI® in the At-Home Setting

    Live event to be held on Thursday, April 23, at 2:00 p.m. ET  Company focused on advancing launch strategy ahead of November 14 PDUFA target action date NEW HAVEN, Conn., April 17, 2026 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (NASDAQ:BTAI), a biopharmaceutical company built on artificial intelligence ("AI") to develop transformative medicines in neuroscience, today announced it will host a virtual event on Thursday, April 23, from 2:00 to 3:00 p.m. ET.  The event will center on the Company's ongoing launch strategy initiatives ahead of the November 14 PDUFA target action date of IGALMI® for the treatment of acute agitation associated with bipolar disorders and schizophrenia in th

    4/17/26 7:00:00 AM ET
    $BTAI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BTAI
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Scientific Officer Yocca Frank converted options into 17,500 shares and sold $7,427 worth of shares (6,845 units at $1.08) as part of a pre-agreed trading plan, increasing direct ownership by 69% to 26,175 units (SEC Form 4)

    4 - BioXcel Therapeutics, Inc. (0001720893) (Issuer)

    5/22/26 7:02:45 PM ET
    $BTAI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Officer Rodriguez Javier converted options into 17,500 shares and sold $7,111 worth of shares (6,560 units at $1.08) as part of a pre-agreed trading plan, increasing direct ownership by 69% to 26,803 units (SEC Form 4)

    4 - BioXcel Therapeutics, Inc. (0001720893) (Issuer)

    5/22/26 7:02:11 PM ET
    $BTAI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Financial Officer Steinhart Richard I converted options into 17,500 shares and sold $7,427 worth of shares (6,845 units at $1.08) as part of a pre-agreed trading plan, increasing direct ownership by 68% to 26,300 units (SEC Form 4)

    4 - BioXcel Therapeutics, Inc. (0001720893) (Issuer)

    5/22/26 7:01:40 PM ET
    $BTAI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BTAI
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Rodman & Renshaw initiated coverage on BioXcel Therapeutics with a new price target

    Rodman & Renshaw initiated coverage of BioXcel Therapeutics with a rating of Buy and set a new price target of $17.00

    3/17/26 8:16:49 AM ET
    $BTAI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    BioXcel Therapeutics downgraded by UBS with a new price target

    UBS downgraded BioXcel Therapeutics from Buy to Neutral and set a new price target of $4.00 from $9.00 previously

    2/21/24 8:16:51 AM ET
    $BTAI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    BioXcel Therapeutics downgraded by Mizuho with a new price target

    Mizuho downgraded BioXcel Therapeutics from Buy to Neutral and set a new price target of $4.00 from $40.00 previously

    8/15/23 7:17:23 AM ET
    $BTAI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BTAI
    Financials

    Live finance-specific insights

    View All

    UPDATE -- BioXcel Therapeutics Announces SERENITY At-Home Pivotal Phase 3 Safety Trial Met its Primary Endpoint in Support of sNDA Submission for Label Expansion of IGALMI®

    BXCL501 achieved SERENITY At-Home's primary endpoint of being well tolerated in the at-home treatment of agitation episodes in patients with bipolar disorders or schizophrenia No discontinuations for tolerability in the BXCL501 arm While not the primary objective of the SERENITY At-Home trial, the preliminary results demonstrate continued effects and consistent benefit with repeat dosing across the course of the trial Following previously disclosed positive FDA feedback, BioXcel plans to submit a sNDA in Q1 2026 for expanded usage of BXCL501 in the outpatient setting without the supervision of a healthcare provider More than 2400 episodes of agitation were treated in the SERENITY At-Home

    8/27/25 8:00:16 AM ET
    $BTAI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    BioXcel Therapeutics Announces SERENITY At-Home Pivotal Phase 3 Safety Trial Met its Primary Endpoint in Support of sNDA Submission for Label Expansion of IGALMI®

    BXCL501 achieved SERENITY At-Home's primary endpoint of being well tolerated in the at-home treatment of agitation episodes in patients with bipolar disorders or schizophrenia No discontinuations for tolerability in the BXCL501 arm While not the primary objective of the SERENITY At-Home trial, the preliminary results demonstrate continued effects and consistent benefit with repeat dosing across the course of the trial Following previously disclosed positive FDA feedback, BioXcel plans to submit a sNDA in Q1 2026 for expanded usage of BXCL501 in the outpatient setting without the supervision of a healthcare provider More than 2400 episodes of agitation were treated in the SERENITY

    8/27/25 7:00:00 AM ET
    $BTAI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    BioXcel Therapeutics Reports Financial Results for the Fourth Quarter and Full Year 2024

    Enrollment exceeds 60% of required number of patients in SERENITY At-Home pivotal Phase 3 safety trial evaluating 200 patients for acute treatment of agitation associated with bipolar disorders or schizophrenia Topline data expected in second half of 2025 intended to support potential sNDA submission for label expansion of IGALMI® in the at-home setting Strengthened cash position to advance BXCL501 program NEW HAVEN, Conn., March 27, 2025 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (NASDAQ:BTAI), a biopharmaceutical company utilizing artificial intelligence to develop transformative medicines in neuroscience, today reported its financial results for the fourth quarter and full year 2

    3/27/25 7:00:00 AM ET
    $BTAI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BTAI
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by BioXcel Therapeutics Inc.

    SC 13G/A - BioXcel Therapeutics, Inc. (0001720893) (Subject)

    9/10/24 10:47:52 AM ET
    $BTAI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13D/A filed by BioXcel Therapeutics Inc. (Amendment)

    SC 13D/A - BioXcel Therapeutics, Inc. (0001720893) (Subject)

    6/6/24 8:29:42 PM ET
    $BTAI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by BioXcel Therapeutics Inc. (Amendment)

    SC 13G/A - BioXcel Therapeutics, Inc. (0001720893) (Subject)

    2/9/24 8:35:57 AM ET
    $BTAI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BTAI
    Leadership Updates

    Live Leadership Updates

    View All

    BioXcel Therapeutics Expands Leadership Team to Prepare for Launch of IGALMI® in the At-Home Setting

    Mark Pavao to Join BioXcel Therapeutics as Interim Chief Commercial Officer Mr. Pavao Brings Deep Experience in Neuroscience Sales and Marketing to Support Potential Launch of IGALMI® in At-Home Setting as Early as Year-End 2026 BioXcel Therapeutics on Track to Submit a sNDA for IGALMI® this Month NEW HAVEN, Conn., Jan. 12, 2026 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (NASDAQ:BTAI), a biopharmaceutical company built on artificial intelligence ("AI") to develop transformative medicines in neuroscience, today announced the advancement of its commercial planning for IGALMI® in the at-home setting. As part of this, Mark Pavao, a commercial planning and launch advisor with more than 3

    1/12/26 7:00:00 AM ET
    $BTAI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    BioXcel Therapeutics Strengthens Clinical Development Leadership to Advance Late-Stage Programs

    Vincent J. O'Neill, M.D., promoted to Executive Vice President, Chief of Product Development and Medical Officer   Rajiv Patni, M.D., appointed Strategic Clinical Advisor to CEO and Board of Directors NEW HAVEN, Conn., Dec. 11, 2023 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (NASDAQ:BTAI), a biopharmaceutical company utilizing artificial intelligence to develop transformative medicines in neuroscience and immuno-oncology, today announced a key executive promotion and a clinical advisor appointment as part of the Company's strategic reprioritization focused on the advancement of its late-stage clinical programs and emerging pipeline candidates. Vincent J. O'Neill, M.D., Senior Vice

    12/11/23 7:00:00 AM ET
    $BTAI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    BioXcel Therapeutics Appoints Michael P. Miller to Board of Directors

    NEW HAVEN, Conn., July 05, 2022 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (NASDAQ:BTAI), a commercial-stage biopharmaceutical company utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology, today announced the appointment of Michael P. Miller to its Board of Directors, effective July 1, 2022. Mr. Miller brings nearly 40 years of strategic leadership and commercial growth experience in the pharmaceutical industry, where he most recently served as Executive Vice President, U.S. Commercial at Jazz Pharmaceuticals. "We are pleased to welcome Mike to our Board and believe his deep commercial and market access expertise will be

    7/5/22 7:00:00 AM ET
    $BTAI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BTAI
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    FDA Approval for IGALMI issued to BIOXCEL THERAPEUTICS, INC.

    Submission status for BIOXCEL THERAPEUTICS, INC.'s drug IGALMI (ORIG-1) with active ingredient DEXMEDETOMIDINE has changed to 'Approval' on 04/05/2022. Application Category: NDA, Application Number: 215390, Application Classification: Type 3 - New Dosage Form

    4/6/22 2:18:32 PM ET
    $BTAI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BTAI
    SEC Filings

    View All

    SEC Form 144 filed by BioXcel Therapeutics Inc.

    144 - BioXcel Therapeutics, Inc. (0001720893) (Subject)

    5/20/26 4:25:20 PM ET
    $BTAI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SCHEDULE 13G filed by BioXcel Therapeutics Inc.

    SCHEDULE 13G - BioXcel Therapeutics, Inc. (0001720893) (Subject)

    5/15/26 11:09:47 AM ET
    $BTAI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    BioXcel Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - BioXcel Therapeutics, Inc. (0001720893) (Filer)

    5/15/26 7:07:13 AM ET
    $BTAI
    Biotechnology: Pharmaceutical Preparations
    Health Care